Iceland Startups and Tech Companies

Iceland has roughly 380,000 people. The Nordic startup directory’s standard population-to-output filter would suggest a handful of small companies and not much else. The actual picture is the opposite, and it’s the most concentrated per-capita biotech and clean-compute story in Europe.

The flagship is Alvotech, the Reykjavik biosimilars company. FY2025 revenue was $593M, up 21% year-over-year, with adjusted EBITDA of $137M (+27%). Q4 2025 alone delivered $173M revenue. The 2026 guidance is $650–700M revenue and $180–220M adjusted EBITDA. The product portfolio is five approved on-market biosimilars (Humira, Stelara, Simponi, Eylea, Prolia/Xgeva) sold into 90 countries via partners, with a 30-asset development pipeline behind them. Alvotech is, in absolute revenue terms, larger than every other Nordic healthcare operator in the directory combined.

The 2025 risk story sits inside a single building. Following a July 2025 FDA inspection of the Reykjavik facility, Alvotech received Complete Response Letters on four BLAs simultaneously. The company plans to resubmit in Q2 2026. The non-obvious read: Alvotech is essentially a single-site manufacturer for a global biosimilars business, which means one Form 483 from one facility can cascade into multiple US approvals being held simultaneously. That is exactly what happened. Whether the second manufacturing site comes online before the next inspection cycle is the underwriting question for the next two years.

Behind Alvotech sits Kerecis, the regenerative-medicine company that sold to Coloplast for $1.3B in 2023 — the largest-ever Icelandic exit and one of the largest Nordic biotech exits of the cycle. Sidekick Health covers digital therapeutics. The directory bench is small but unusually dense by per-capita measures.

The under-discussed advantage is energy. Iceland’s electricity is roughly 100% renewable (geothermal and hydro), and the country has surplus capacity beyond domestic demand. That makes Reykjavik one of the cheapest places in the EEA to operate compute-intensive AI workloads, and hyperscaler tenant capacity is physically migrating to Icelandic data centres in ways that don’t show up in startup activity reports but reshape the country’s economic surface. For an AI company with serious GPU-bound compute requirements, the Iceland compute cost story is genuinely competitive in a way no other Nordic capital can match physically.

Innovation Centre Iceland is the public agency, and it operates at a scale matched to the population — a senior decision-maker is reachable in a way Brussels is not. Reykjavik University and the University of Iceland supply the technical pipeline, with biotech and computational sciences disproportionately represented. The labour pool is small enough that hiring 30 senior people fast is genuinely a constraint; the flip side is that the network effects within the country are strong enough that recruitment via warm intro is more reliable than in any other Nordic capital.

The 2026 question is whether Iceland diversifies beyond its single flagship. The country has produced exactly one half-billion-dollar revenue operator and a small handful of consequential exits. Sweden’s diversification across hundreds of mid-scale companies is the structural advantage Iceland does not match. The flip side is that per-capita output and per-capita talent density are the highest in the Nordic directory, and the geothermal-compute story is a structural advantage that Iceland will keep regardless of how the biotech bench evolves.

For anyone scoping a Nordic base, Iceland is the right answer for specialised biotech with abundant compute requirements, AI-heavy products with serious energy budgets, and any deeptech team that wants the lowest possible cost-of-compute clean energy. The country is the wrong answer for products that need a 200-person engineering hire in year one — that’s a Stockholm or Helsinki conversation. Cross-reference the directory’s Iceland listings for the full bench.